FDA Approved: CAMPATH — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

FDA approved a supplemental application for CAMPATH (alemtuzumab) filed by Genzyme Corporation to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

SUPPL AP for CAMPATH (ALEMTUZUMAB)